TGA takes strong action to protect Australians from unlawful therapeutic goods
Published
Related content
-
TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response
We have expanded our priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply and advertising, posing potential risks to consumer safety. -
The TGA releases compliance principles, reinforcing proactive and risk-based enforcement throughout 2026 and 2027
The TGA Compliance Principles 2026 and 2027 outlines our strategic approach to monitoring and enforcing regulatory compliance for the import, export, manufacture, supply and advertising of therapeutic goods in Australia. -
TGA seizes 70,000 vapes in NSW
We have executed warrants on storage units in Sydney and seized more than 70,000 vaping products, with an estimated street value of over $2.1 million. They will be tested for dangerous and undeclared chemicals at our labs.